Capsaicin / ENOX2 Cancer Research Results

CAP, Capsaicin: Click to Expand ⟱
Features:
Capsaicin is a chemical compound that gives chili peppers their spicy flavor and heat.

Biological activity, capsaicin has been reported to exhibit a range of effects, including:
Pain relief: 10-50 μM
Anti-inflammatory activity: 20-50 μM
Antioxidant activity: 10-100 μM
Anti-cancer activity: 50-100 μM
Cardiovascular health: 20-50 μM

Approximate μM concentrations of capsaicin, the active compound in chili peppers, that can be achieved with different amounts of chili peppers:
1 teaspoon of dried chili pepper flakes (5g):~10-50 μM of capsaicin
1 tablespoon of dried chili pepper flakes (15g): ~30-150 μM of capsaicin
1 cup of fresh chili peppers (100g): ~100-500 μM of capsaicin
1 teaspoon of chili pepper extract (5g): ~100-500 μM of capsaicin
1 tablespoon of chili pepper extract (15g): ~300-1500 μM of capsaicin

Approximate μM concentrations of capsaicin in various foods that contain capsaicin:
Jalapeño peppers: 1 pepper (20g): ~20-100 μM of capsaicin 2–8 mg/100g of fresh Jalapeño
Serrano peppers: 1 pepper (10g): ~10-50 μM of capsaicin 5–15 mg/100g
Cayenne peppers: 1 pepper (10g): ~50-200 μM of capsaicin
Habanero peppers: 1 pepper (20g): ~100-500 μM of capsaicin 15–30 mg/100g
Ghost peppers: 1 pepper (20g): ~200-1000 μM of capsaicin
Hot sauce: 1 teaspoon (5g): ~10-50 μM of capsaicin
Chili flakes: 1 teaspoon (5g): ~10-50 μM of capsaicin
Spicy sauces and marinades: 1 tablespoon (15g): ~10-50 μM of capsaicin

Cayenne Pepper Powder – Approximate capsaicin content: roughly 5–20 mg/g (15-30g human for 100uM?)

-IC50 in Cancer Cell Lines: Approximately 50–300 µM (consume 150mg of capsaican not possible?)
-IC50 in Normal Cell Lines: Generally higher—often 2–3 times greater

Pathways:
-disrupting mitochondrial membrane potential, leading to cytochrome c release and subsequent activation of caspases
-Activation of TRPV1: resulting in increased intracellular calcium levels
-capsaicin can lead to increased production of ROS within cancer cells
-Inhibition of NF-κB
-Inhibit PI3K/AKT/mTOR signaling
-STAT3 Inhibition
-Cell Cycle Arrest
-reduce the expression of vascular endothelial growth factor (VEGF)
-COX-2
-capsaicin is a natural ADAM10 activator and shows potential to attenuate amyloid pathology and protect against AD

Capsaicin — capsaicin is a pungent vanilloid alkaloid phytochemical from Capsicum peppers and the principal TRPV1 agonist responsible for chili heat. It is best classified as a natural product / small-molecule vanilloid with approved topical analgesic use but no established anticancer indication. Standard abbreviations include CAP and CAPS. In cancer literature it is a pleiotropic stressor whose dominant preclinical effects usually converge on Ca2+ influx, mitochondrial dysfunction, ROS generation, suppression of pro-survival signaling, and apoptosis, but its biology is context- and concentration-dependent, with occasional low-dose pro-migratory / pro-metastatic signaling reported.

Primary mechanisms (ranked):

  1. TRPV-linked cation influx with intracellular Ca2+ dysregulation, variably via TRPV1 or other TRPV-family context such as TRPV6
  2. Mitochondrial injury with loss of membrane potential, cytochrome c release, and intrinsic apoptotic execution
  3. Mitochondrial and cellular ROS increase with redox stress exceeding tumor buffering capacity
  4. Suppression of STAT3 and related survival transcription programs in multiple models
  5. Suppression of NF-κB-centered inflammatory / survival signaling, with downstream anti-migratory and radiosensitizing implications in some settings
  6. PI3K/Akt/mTOR attenuation and cell-cycle restraint in responsive models
  7. Contextual induction of autophagy as a stress-adaptation program that may either accompany death or partially buffer it
  8. Anti-migratory / anti-invasive effects in many models, but with an important low-concentration exception in some colorectal systems

Bioavailability / PK relevance: Capsaicin is lipophilic, rapidly absorbed, and rapidly metabolized, with substantial first-pass limitation after oral exposure. Human oral PK from a capsicum preparation containing 26.6 mg capsaicin produced a Cmax of about 2.47 ng/mL at ~47 minutes, while the FDA-approved 8% topical system produced transient systemic exposure usually below 5 ng/mL, with a highest detected plasma level of 4.6 ng/mL. Delivery is therefore a major translation constraint for anticancer use, and formulation-based approaches are often invoked to overcome short half-life, irritancy, and exposure limits.

In-vitro vs systemic exposure relevance: This is a major limitation. Many anticancer cell studies use roughly 10–300 µM, whereas reported human plasma exposures from oral or approved topical use are in the low ng/mL range, approximately ~0.008–0.015 µM, i.e., orders of magnitude lower than many cytotoxic in-vitro concentrations. Accordingly, direct systemic tumoricidal translation from standard dietary or approved topical exposure is weak unless local delivery, sustained-release systems, or substantially altered formulations are used.

Clinical evidence status: Anticancer evidence is predominantly preclinical, with in-vitro and some in-vivo support across several tumor types. There is no regulatory approval for cancer treatment. Human oncology use is currently much more credible as supportive care for neuropathic pain, especially chemotherapy-induced peripheral neuropathy, where topical high-concentration capsaicin patches are being studied and used off-label / investigationally, rather than as a direct antitumor therapy.

Mechanistic Table

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 TRPV-linked Ca2+ influx Ca2+ ↑; death signaling ↑ Sensory excitation ↑; irritancy ↑ P/R Upstream trigger Usually framed through TRPV1, but some tumor models show dependence on other TRPV-family context such as TRPV6; this is mechanistically central but not uniform across cancers.
2 Mitochondrial membrane potential MMP ↓; cytochrome c release ↑ ↔ / stress if exposed R Intrinsic apoptosis initiation Mitochondrial dysfunction is one of the most reproducible downstream events and often links Ca2+ overload with apoptosis.
3 Mitochondrial ROS increase ROS ↑; redox buffering overwhelmed ↔ / antioxidant response may compensate P/R Stress amplification Frequently sits upstream of mitochondrial collapse, DNA damage signaling, and apoptosis; cancer selectivity is often attributed to weaker redox reserve.
4 Intrinsic apoptosis machinery BAX/Bak ↑; Bcl-2/Bcl-xL ↓; caspase-3/9 ↑ ↔ / lower sensitivity in some comparisons R/G Execution-phase cell death Common endpoint across responsive models; often follows ROS and mitochondrial injury rather than acting as the primary initiating lesion.
5 STAT3 survival signaling STAT3 ↓ ↔ R/G Reduced survival and proliferation Well supported in multiple myeloma and other models, but not universal; note that a HepG2 context reported ROS-associated STAT3 activation coupled to autophagy.
6 NF-κB inflammatory survival axis NF-κB ↓ Inflammatory tone ↓ R/G Anti-survival; anti-migratory Important for invasion restraint and likely part of observed radiosensitization in some models.
7 PI3K Akt mTOR axis PI3K/Akt/mTOR ↓ ↔ R/G Growth suppression Seen in several responsive systems, but this axis is also part of the cautionary low-dose pro-metastatic literature in colorectal cancer.
8 Cell-cycle control G0/G1 or G1/S arrest ↑ ↔ G Proliferation blockade Usually secondary to upstream stress and survival-pathway suppression rather than the earliest event.
9 Autophagy stress program Autophagy ↑ (context-dependent) ↔ G Adaptive buffering or co-lethal stress In HepG2, autophagy appeared partially protective because inhibiting it enhanced capsaicin-induced apoptosis.
10 Migration invasion EMT phenotype Migration ↓; invasion ↓; EMT ↓ (context-dependent) ↔ G Anti-metastatic phenotype Frequently reported at active doses, often linked to AMPK activation and NF-κB suppression.
11 Low-dose paradox flag ROS ↑ with Akt/mTOR ↑ and STAT3 ↑ (model-dependent) ↔ G Potential pro-metastatic signaling Important caution: low-concentration capsaicin has been reported to enhance metastatic behavior in colorectal cancer models.
12 Radiosensitization or Chemosensitization Sensitivity ↑ (context-dependent) Unknown G Adjunct potential Preclinical support exists, especially via NF-κB and stress-pathway modulation, but this remains non-clinically established for direct cancer treatment.
13 Clinical Translation Constraint Required tumoricidal exposure often not reached systemically Irritation and tolerability limit escalation G Translation bottleneck Typical antitumor in-vitro concentrations greatly exceed known plasma exposure from standard oral intake or approved topical use; formulation, local delivery, and tumor heterogeneity are major constraints.

P: 0–30 min

R: 30 min–3 hr

G: >3 hr
ENOX2, NADH oxidases: Click to Expand ⟱
Source:
Type: "cancer-specific" cell surface marker
NADH oxidases (often referred to as tNOX/ENOX2)
tNOX stands for "tumor-associated NADH oxidase," and it is also known as ENOX2.
ENOX2 (Ecto-Nicotinamide Adenine Dinucleotide Oxidase Disulfide-Thiol Exchanger 2) is a protein that has drawn attention in the context of cancer.
ENOX2 is an enzyme found on the cell surface that exhibits NADH oxidase activity along with protein disulfide-thiol interchange activity.
Several studies have suggested that ENOX2 could be used as a biomarker for cancer diagnosis, prognosis, and monitoring.

NADH oxidases (often referred to as tNOX/ENOX2) and NADPH oxidase family members that have been implicated in redox regulation—detailing their expression in various cancers as well as correlations with prognosis.

– tNOX (also known as ENOX2) is a cancer‐specific cell surface NADH oxidase with a role in cellular growth regulation.
– This enzyme cycles between hydroquinone oxidase and protein disulfide-thiol interchange activities and is generally not expressed in normal cells.

• Expression in Cancer & Prognosis:
– ENOX2 is overexpressed in many solid tumors, including breast, prostate, lung, colon, and various hematologic malignancies.
– Elevated ENOX2 levels in patient sera or tumor samples have been correlated with aggressive tumor behavior and poor prognosis.
– The presence of ENOX2 activity often indicates an increased rate of cell proliferation and may predict recurrence after treatment.

ENOX2 is specifically expressed on the cell surface of many cancer cells and is involved in redox regulation and the control of cellular growth.
Because ENOX2 is predominantly expressed in tumors rather than normal tissues, it has been explored as a potential diagnostic and prognostic biomarker in oncology.

ENOX2 is frequently upregulated or more active in cancer cells.
By influencing the balance between NADH and NAD⁺, ENOX2 might shift the cellular redox state. An imbalance can lead to increased oxidative stress or changes in ROS signaling pathways.

Potential Effects of Inhibition (**** ROS increase ****)
When ENOX2 is inhibited, its NADH oxidase activity is reduced. This can lead to an altered cell redox state.
Some studies suggest that blocking ENOX2 activity in cancer cells disrupts their normal redox homeostasis. In certain cases, this disruption may result in the accumulation of NADH and/or an alteration in electron flow—conditions that can favor increased ROS production. Increased ROS can lead to oxidative stress that may trigger cell death (e.g., via apoptosis), which is one of the reasons researchers are interested in ENOX2 as a target for cancer therapy. While there is evidence that inhibiting ENOX2 can lead to an increase in ROS—contributing to oxidative stress and potentially cell death—this outcome is not universal.
Scientific Papers found: Click to Expand⟱
1518- CAP,    Capsaicin-mediated tNOX (ENOX2) up-regulation enhances cell proliferation and migration in vitro and in vivo
- in-vitro, CRC, HCT116
ENOX2↑, TumCP↑, TumCMig↑, Dose?, eff↑,
1517- CAP,    Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)
- in-vitro, Bladder, TSGH8301 - in-vitro, CRC, T24/HTB-9
ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1/CCND1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,
693- EGCG,  CAP,  Phen,    Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol
- in-vitro, Cerv, HeLa
ENOX2↓, TumCG↓,
637- EGCG,  CAP,    Cancer prevention trial of a synergistic mixture of green tea concentrate plus Capsicum (CAPSOL-T) in a random population of subjects ages 40-84
- Human, NA, NA
ENOX2↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ENOX2↓, 3,   ENOX2↑, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

SIRT1↓, 2,  

Cell Death ⓘ

Bak↑, 1,   Bcl-2↓, 1,   BIM↑, 1,   Casp3↑, 1,  

DNA Damage & Repair ⓘ

ac‑P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   p‑RB1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   ERK↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   p‑FAK↓, 1,   N-cadherin↓, 1,   p‑pax↓, 1,   TumCMig↓, 1,   TumCMig↑, 1,   TumCP↑, 1,   β-catenin/ZEB1↓, 1,  

Drug Metabolism & Resistance ⓘ

Dose?, 1,   Dose∅, 2,   eff↑, 1,  
Total Targets: 28

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: ENOX2, NADH oxidases
4 Capsaicin
2 EGCG (Epigallocatechin Gallate)
1 PXD, phenoxodiol
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:55  Target#:822  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page